



HAL
open science

Streptogramins for the treatment of infections caused by Gram-positive pathogens.

Sophie Reissier, Vincent Cattoir

► To cite this version:

Sophie Reissier, Vincent Cattoir. Streptogramins for the treatment of infections caused by Gram-positive pathogens.. Expert Review of Anti-infective Therapy, 2021, pp.1-13. 10.1080/14787210.2021.1834851 . hal-03000655

HAL Id: hal-03000655

<https://hal.science/hal-03000655>

Submitted on 5 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Streptogramins for the treatment of infections caused by
Gram-positive pathogens**

Sophie Reissier ¹, Vincent Cattoir ^{1 2 3}

1 Université De Rennes 1, Unité Inserm U1230 , Rennes, France.

2 Service De Bactériologie-Hygiène Hospitalière, CHU De Rennes , Rennes, France.

3 Centre National De Référence De La Résistance Aux Antibiotiques (Laboratoire Associé 'Entérocoques'), CHU De Rennes , Rennes, France.

1
2
3 **1 Abstract**

4
5 **2 Introduction:** Streptogramins (pristinamycin and quinupristin-dalfopristin) can be interesting
6
7
8 options for the treatment of infections due to Gram-positive cocci, especially multidrug-
9
10 resistant isolates.

11
12 **3 Areas covered:** This review provides an updated overview on structural and activity
13
14 characteristics, mechanisms of action and resistance, pharmacokinetic/pharmacodynamic and
15
16 clinical use of streptogramins.

17
18 **4 Expert opinion:** The streptogramin antibiotics act by inhibition of the bacterial protein
19
20 synthesis. They are composed of two chemically distinct compounds, namely type A and type
21
22 B streptogramins, which exert a rapid bactericidal activity against a wide range of Gram-
23
24 positive bacteria (including methicillin-resistant staphylococci and vancomycin-resistant
25
26 enterococci). Several mechanisms of resistance have been identified in staphylococci and
27
28 enterococci but the prevalence of streptogramin resistance among clinical isolates remains
29
30 very low. Even if only a few randomized clinical trials have been conducted, the efficacy of
31
32 pristinamycin has been largely demonstrated with an extensive use for 50 years in France and
33
34 some African countries. Despite its effectiveness in the treatment of severe Gram-positive
35
36 bacterial infections demonstrated in several studies and the low rate of reported resistance, the
37
38 clinical use quinupristin-dalfopristin has remained limited, mainly due to its its poor
39
40 tolerance. Altogether, streptogramins (especially pristinamycin) can be considered as
41
42 potential alternatives for the treatment of Gram-positive infections.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

Staphylococci, streptococci and enterococci are major Gram-positive bacterial pathogens causing infections both in the community and in hospitals [1]. Methicillin-resistant *Staphylococcus aureus* (MRSA) is still a major cause of nosocomial infections, while the emergence of infections caused by community-acquired MRSA (CA-MRSA) has been reported worldwide, especially in the US [2]. Glycopeptides are the first line antibiotics used to treat MRSA infections, but since 1997, *S. aureus* strains with reduced susceptibility or resistance to glycopeptides have been described and still remain a global concern [3]. Coagulase-negative staphylococci (CoNS) emerged as a major cause of hospital-acquired infections (e.g. catheter-related bacteremia, endocarditis, osteoarticular and neonatal infections) and are often resistant to multiple antibiotics [4–6]. Due to their capacity to acquire and accumulate numerous antibiotic resistance determinants, enterococci, especially vancomycin-resistant *Enterococcus faecium* (VREF), have become major opportunistic pathogens in hospitals, strongly limiting the range of therapeutic options [7]. Even if widespread use of the pediatric pneumococcal conjugate vaccine has significantly decreased morbidity and mortality of infections due to *Streptococcus pneumoniae* in all age groups, there has been an unexpected increase of serotypes uncovered by the vaccine (e.g. 35B) as well as antibiotic-resistant serotypes (e.g. 19A) in some regions [8,9].

Besides the emergence of infections caused by multidrug-resistant (MDR) Gram-positive bacteria, which results in a significant increase of morbidity, mortality, and health cost, there is also a paucity of new antibacterial drugs developed by pharmaceutical companies [10,11]. Therefore, current antimicrobial alternatives for the treatment of severe infections are scarce, taking account into the risk of the emergence of bacterial resistance, the need of intravenous access, side effects and contraindications[12]. Many complex infections due to these MDR microorganisms (such as prosthetic joint infections) also require prolonged antibiotic therapy,

1
2
3 46 with an intravenous-to-oral switch therapy. Oral therapeutic options would be also beneficial,
4
5 47 for the ambulatory treatment of community-acquired infections.
6

7 48 Streptogramins have been considered as potential alternatives for the treatment of Gram-
8
9
10 49 positive infections, because of their rapid bactericidal activity against a wide range of Gram-
11
12 50 positive bacteria (including MDR strains), their low prevalence of resistance among clinical
13
14 51 isolates, and their good pharmacokinetic properties [13,14]. Streptogramins are also effective
15
16 52 against Gram-negative cocci such as *Neisseria spp* or *Moraxella catarrhalis*. To date, two
17
18 53 streptogramins are prescribed in human medicine. Oral pristinamycin (formerly RP 7293),
19
20 54 commercialized under the name Pyostacine® (Sanofi-Aventis, Gentilly, France), is
21
22 55 extensively used for 50 years in France, and is currently used in France, Tunisia and
23
24 56 Lithuania. Quinupristin-dalfopristin (formerly RP 59500), marketed under the name
25
26 57 Synercid® (Pzifer, New York), is an injectable formulation approved since 1999 and 2000 in
27
28 58 the US and Europe, respectively. Quinupristine-dalfopristine is now only used in the US.
29
30
31 59 Another oral streptogramin, NXL 103 (formerly XRP 2868), underwent phase II clinical trial
32
33 60 in 2011 but has not been distributed [15]. Of note, virginiamycin, an oral streptogramin, was
34
35 61 therapeutically used in France until late 1990s and as a growth promoter for animals in many
36
37 62 European countries until early 2000s and currently in the US, China, Japan and Canada [16].
38
39 63 Virginiamycin is also used to prevent bacterial contamination in ethanol fuel industry [17].
40
41
42
43

44 64 Several reviews have already been published about streptogramins but they mainly dealt
45
46 65 with structure, mode of action or biosynthesis and its regulation [16,18]. Here we have
47
48 66 chosen to focus on clinical uses, to synthesize clinical studies on each molecule, current
49
50 67 recommendations for use as well as trials about new molecules.
51

52 68 2. Structure

53
54 69 The streptogramin antibiotics are composed of two chemically distinct compounds, namely
55
56 70 type A and type B streptogramins [18]. The type A streptogramins are polyunsaturated cyclic
57
58
59
60

1
2
3 71 macrolactones (ca. 500 Da) containing an unusual oxazole ring and a dienyl amide fragment,
4
5 72 whereas type B streptogramins are cyclic hepta- or hexadepsipeptides (ca. 800 Da) with a
6
7 73 skeleton of amino acids with variations depending on the compound (**Figure 1**) [18–20].
8
9
10 74 Originally, streptogramins are natural mixtures produced by different members of
11
12 75 *Streptomyces* or related genera (**Table 1**) [19,21]. Every antibiotic producer synthesizes a
13
14 76 mixture of various A and B components **in different proportions**. For instance, *Streptomyces*
15
16 77 *pristinaespiralis* produces a mixture of group B compounds called pristinamycins I
17
18 78 (pristinamycin I_A, pristinamycin I_B, and pristinamycin I_C with a ratio of 80-90%, 3-5%, and 2-
19
20 79 5%, respectively) and a mixture of group A compounds called pristinamycins II
21
22 80 (pristinamycin II_A and pristinamycin II_B) [19]. Note that pristinamycin II_A is predominant in
23
24 81 the pristinamycin II mixture. The relative proportion of the different pristinamycin II
25
26 82 fermentation products also depends on culture conditions [20]. Finally, the pristinamycin
27
28 83 produced by *S. pristinaespiralis* is a mixture of pristinamycin I_A and pristinamycin II_A in a
29
30 84 30:70 ratio by weight (**Table 1 & Figure 1**) [19,20].
31
32
33
34

35 85 Since a limitation in the clinical use of streptogramins was the poor water solubility, which
36
37 86 prevented the availability of an injectable form for the treatment of severe infections, semi-
38
39 87 synthetic derivatives were developed in the 1990s from natural pristinamycins (**Table 1**) [19].
40
41 88 Quinupristin (RP 57669) and dalfopristin (RP 54476) were obtained after several steps of
42
43 89 chemical modifications from pristinamycin II_A and pristinamycin I_A, respectively [19]. The
44
45 90 streptogramin association selected, comprised quinupristin and dalfopristin combined in a
46
47 91 30:70 ratio (w/w) of methane sulfonate salts as RP 59500 (**Figure 1**) [19,20].
48
49
50

51 92 **3. Mechanism of action**

52
53 93 Streptogramins A and B act by interfering with bacterial protein synthesis [22,23]. Their
54
55 94 bindings to adjacent but distinct regions within the P site of 23S rRNA of the 50S ribosomal
56
57 95 subunit result in synergic inhibiting activity [24]. Due to cooperative binding, streptogramin
58
59
60

1
2
3 96 compounds, which are separately bacteriostatic against most Gram-positive bacteria, act
4
5 97 synergistically *in vitro* and *in vivo* and usually become bactericidal when combined [22].
6

7 98 Type A streptogramins block tRNAs attachment to both A and P sites of the peptidyl-
9 99 transferase center (PTC), and thus preventing the two early steps of elongation (i.e.
10 100 aminoacyl-tRNA binding to the A site and peptide bond formation with peptidyl-tRNA at the
11 101 P site) (Figure 2) [21,22]. Initially, it was thought that streptogramins A were only able to
12 102 bind to 50S subunits and free 70S ribosomes and not to ribosomes involved into protein
13 103 synthesis and polysomes [22]. However, it has been demonstrated that streptogramins A also
14 104 interact with the entrance of the peptide exit tunnel, and likely bind to translating ribosomes
15 105 [25]. Type B streptogramins share overlapping binding sites with macrolides and
16 106 lincosamides (domains II and V of the 23S rRNA), and act similarly by inhibiting
17 107 translocation, preventing polypeptide extension, and triggering the premature release of
18 108 incomplete protein chains [21,22]. Streptogramins B binding site is located at the entrance to
19 109 the ribosome tunnel, and does not contact the PTC (Figure 2) [26]. They can interact with
20 110 ribosomes at any step of protein synthesis, including translating ribosomes and polysomes,
21 111 inhibiting elongation after a few cycles [22].
22
23
24
25
26
27
28
29
30
31
32

33 112 In addition, binding of type A streptogramins induces a conformational change in the
34 113 ribosome near the PTC that subsequently unmasks a high-affinity binding site for
35 114 streptogramins B leading to an increase of their activity by ca. 100-fold [18,21,22]. This
36 115 synergy in the binding of streptogramins A and B seems to result from a repositioning of a
37 116 single nucleotide, A2062 (*Escherichia coli* numbering), permitting direct interactions between
38 117 both compounds [26,27]. Finally, the bactericidal activity of streptogramins may be partially
39 118 due to the induction of a conformational alteration of U2585, leading to a hydrogen-bond-
40 119 stabilized distortion of the PTC [26].
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 120 4. Antibacterial activity

58
59
60

1
2
3 121 The spectrum of activity of streptogramins includes a broad range of aerobic and anaerobic
4
5 122 Gram-positive bacteria, with a MIC₉₀ generally ≤ 1 mg/l (**Table 2**) [28–33]. They are active
6
7 123 against methicillin-susceptible, **MRSA** and most of *E. faecium* isolates (including VREF)
8
9 124 (**Table 2**) [30,34]. Noteworthy, *Enterococcus faecalis* is a gap in the antimicrobial spectrum
10
11 125 since this Gram-positive species is intrinsically resistant to type A streptogramins (phenotype
12
13 126 LS_A, **which results in lincosamide and streptogramins A resistance**) and to the A plus B
14
15 127 streptogramin combinations, due to the presence of the *lsa(A)* gene [35–37]. Streptogramins
16
17 128 are also active against *S. pneumoniae* (regardless of resistance to β -lactams and macrolides),
18
19 129 β -hemolytic streptococci, viridans streptococci, *Corynebacterium* spp., and *Listeria*
20
21 130 *monocytogenes* (**Table 2**) [28,38,39]. In addition, streptogramins exhibit activity against most
22
23 131 of Gram-positive anaerobes, such as *Actinomyces* spp., *Clostridium* spp., *Lactobacillus* spp.,
24
25 132 *Peptostreptococcus* spp., and *Cutibacterium acnes* (**Table 2**) [33,39]. They are also active
26
27 133 against *Mycoplasma* spp., *Ureaplasma urealyticum*, and *Chlamydia* spp. Indeed, European
28
29 134 guidelines about *M. genitalium* infections recommend pristinamycin as third-line therapy in
30
31 135 patients failing both azithromycin and moxifloxacin **therapy** [40,41]. Interestingly, they also
32
33 136 have a good activity against fastidious Gram-negative bacteria including *Moraxella*
34
35 137 *catarrhalis*, *Neisseria* spp., and *Legionella pneumophila* (**Table 2**) [28,38,39]. Streptogramins
36
37 138 have a variable activity against *Bacteroides fragilis* group and other Gram-negative
38
39 139 anaerobes. **Several strains are resistant and some, like *Fusobacterium* spp. are very**
40
41 140 **susceptible** (**Table 2**) [28,39,40]. Finally, Enterobacterales, *Pseudomonas aeruginosa*, and
42
43 141 *Acinetobacter* spp. are intrinsically resistant to high levels of streptogramins [28].
44
45
46
47
48
49
50

51 142 **Clinical Laboratory Standards Institute** breakpoints for quinupristin-dalfopristin against
52
53 143 staphylococci, enterococci, and streptococci are as follows: ≤ 1 mg/l, susceptible; 2 mg/l,
54
55 144 intermediate; and ≥ 4 mg/l, resistant [42]. **European Committee of Antimicrobial**
56
57 145 **Susceptibility Testing** breakpoints for quinupristin-dalfopristin are available only for
58
59
60

1
2
3 146 staphylococci (≤ 1 mg/l, susceptible; > 2 mg/l, resistant) and enterococci (≤ 1 mg/l, susceptible;
4
5 147 > 4 mg/l, resistant) (www.eucast.org/). The Antibiogram Committee of the French Society
6
7 148 only recommends breakpoints for pristinamycin for Microbiology ([microbiologie.org](http://www.sfm-
8
9
10 149 2 mg/l, resistant, for staphylococci,
11
12 150 enterococci, streptococci (except *S. pneumoniae*), and anaerobes; ≤ 1 mg/l, susceptible and > 1
13
14 151 mg/l, resistant, for *S. pneumoniae*.

15
16 152 Streptogramins are usually rapidly bactericidal against methicillin-susceptible
17
18 153 staphylococci, streptococci, and pneumococci regardless of erythromycin resistance, with
19
20 154 **minimum bactericidal concentration (MBC)** values usually ≤ 4 -fold higher than those of MICs
21
22
23 155 [29]. However, the bactericidal activity against staphylococci expressing a constitutive cross-
24
25 156 resistance to macrolides, lincosamides, and streptogramins B (like numerous MRSA isolates,
26
27 157 see below) is generally altered [43]. For this reason, clindamycin susceptibility has been
28
29 158 suggested as a surrogate marker for bactericidal activity of quinupristin-dalfopristin against
30
31 159 staphylococci [44,45]. Streptogramins have a bacteriostatic activity against the majority of *E.*
32
33 160 *faecium* isolates [39]. Against MRSA, rifampin has been demonstrated to be synergistic with
34
35 161 quinupristin-dalfopristin while it has been shown a synergism with doxycycline against VREF
36
37 162 [29,46]. Furthermore, the association with doxycycline may prevent or delay the emergence
38
39 163 of resistance **in vitro** and **in vivo** among VREF isolates [29,46,47].

164 **5. Mechanisms of resistance to streptogramins A and B**

165 Most Gram-negative bacteria are intrinsically resistant to streptogramins, owing to the low
166 permeability of the outer membrane and active efflux mechanisms. As already mentioned,
167 type A and B streptogramins are chemically unrelated and have different binding sites on the
168 ribosome. Therefore, different mechanisms will confer resistance to each type of
169 streptogramins. In Gram-positive organisms, a variety of mechanisms confer resistance to
170 either the A or the B component, including modifying enzymes, and modification or

1
2
3 171 protection of the ribosomal target (**Table 3, Figure 3**)
4
5 172 (<http://faculty.washington.edu/marilynr/>) [20,21,48–51].
6

7
8 173 The alteration of the ribosomal target is the most common resistance mechanism to type B
9
10 174 streptogramins [20,21,49–51]. It is mainly due to the post-transcriptional modification of the
11
12 175 23S rRNA (domain V) by an rRNA methylase encoded by *erm* genes (**Table 3**) [20,21,24,49–
13
14 176 51]. Plasmid-borne or transposable *erm* genes encode a ribosomal methylase that mono- or
15
16 177 dimethylates the N⁶ of A2058 (*E. coli* numbering) of the 23S rRNA. This methylation leads to
17
18 178 an alteration of binding of streptogramins B to their target, knowing that the A2058 is the
19
20 179 binding site not only for streptogramins B but also for macrolides and lincosamides, which
21
22 180 have partially overlapping binding sites. This is the reason why this modification confers
23
24 181 cross-resistance to macrolides, lincosamides, and streptogramins B (the so-called MLS_B
25
26 182 phenotype) [20]. To date, more than 40 different *erm* genes have been described
27
28 183 (<http://faculty.washington.edu/marilynr/>) [48,50–55]. Expression of MLS_B resistance can be
29
30 184 constitutive or inducible [20]. In inducible resistance, only the use of erythromycin (and other
31
32 185 14- and 15-membered macrolides) is prohibited, clindamycin and streptogramins B are
33
34 186 remain active. When *erm* genes are expressed constitutively, they confer cross-resistance both
35
36 187 to macrolides, clindamycin, and streptogramins B. Mutations of 23S rRNA and L22
37
38 188 ribosomal proteins, which lead to resistance to streptogramins B, have also been reported,
39
40 189 particularly in *S. pneumoniae* (**Table 3**) [20,48,56].
41
42
43
44
45

46
47 190 Other mechanisms affecting the activity of type B streptogramins are enzymatic
48
49 191 modification (hydrolysis) and ribosome protection. Lyases and lactonases, enzymes encoded
50
51 192 by *vgb* genes, could inactivate streptogramins B (**Table 3**) [20,21,48,50,51]. They cause a
52
53 193 cleavage of the ester linkage leading to a linearization of the molecule. A Low-level of
54
55 194 resistance to streptogramins B, mediated by ribosomal protection through acquisition of *msr*-
56
57 195 like genes, is described in staphylococci, streptococci, or enterococci [57].
58
59
60

1
2
3 196 Drug modification and target modification or protection account for resistance to
4
5 197 streptogramins A [20,21,48–51]. Ribosomal methylation, occurring at a different site than the
6
7 198 A2058 previously mentioned, may confer resistance to type-A streptogramins. Initially
8
9
10 199 identified in staphylococcal isolates from animal sources, the ribosomal methylation
11
12 200 mechanism has been also detected in human *S. aureus* clinical isolates [58–63]. The
13
14 201 resistance is due to the production of the Cfr protein that methylates the 23S rRNA at the
15
16 202 A2503 residue (*E. coli* numbering) (Table 3) [64]. Interestingly, Cfr is responsible for a
17
18 203 cross-resistance to five different antibiotic families: phenicols, lincosamides, oxazolidinones,
19
20 204 pleuromutilins, and streptogramins A (the so-called PhLOPS_A phenotype) [65]. Usually found
21
22 205 on plasmids, the *cfr* gene has also been reported to be encoded on chromosomes [61,66]. Type
23
24 206 A streptogramins can be inactivated through the O-acetylation by acetyltransferases encoded
25
26 207 by *vat* genes (Table 3) [20,21,49–51]. *Vat* enzymes add an acetyl group from acetyl-CoA to
27
28 208 the second hydroxyl of type A streptogramins. Several proteins belonging to the ABC
29
30 209 proteins family including Lsa and Vga proteins are responsible for streptogramin A resistance
31
32 210 in *E. faecalis* and staphylococci through ribosomal protection [48,57,67]. Mutations in *eat(A)*,
33
34 211 which is coding for a ABC protein and conferred acquired LS_A resistance, has also described
35
36 212 in *E. faecium* [68].

213 6. Consequences of resistance mechanisms on synergism between streptogramins A and 214 B

215 In staphylococci, it is possible to select *in vitro* some mutants resistant to quinupristin-
216 dalfopristin, but the frequency remains low (10^{-8} to 10^{-9}) [29]. However, a higher rate of
217 selection has been demonstrated in *E. faecium* [29]. Because of the synergism, acquisition of
218 resistance to each streptogramin type might have no or only partial negative impact on the
219 antimicrobial activity of the combination [20]. Actually, most staphylococcal clinical isolates
220 that express complete resistance to the combination harbour several streptogramin resistance

221 genes such as *vat(A)*, *vgb(A)*, *vga(A)*, *vga(B)* or *vat(B)* [16,48]. In these isolates, *vat(A)*,
222 *vgb(A)*, and *vga(A)* or *vga(B)* and *vat(B)* genes are often associated on plasmids of 26-40 kb
223 and 50-90 kb, respectively [69]. Although streptogramin-resistant clinical isolates of *S. aureus*
224 and *E. faecium* containing such plasmids have already spread, their prevalence remains low
225 [69]. Resistance to the B component of streptogramins due to the constitutive MLS_B
226 phenotype is widespread in staphylococci and streptococci [20,48]. It has been early shown
227 that the synergism between type A and B components is maintained against clinical isolates of
228 staphylococci and streptococci constitutively resistant to macrolides. The original observation
229 of synergy preservation was done with pristinamycin, and was confirmed for quinupristin-
230 dalfopristin [70,71]. Conservation of synergism is likely due to the unique and synergic mode
231 of action of streptogramins (see above). However, as previously mentioned, the *in vitro*
232 bactericidal activity of the combination is altered in staphylococci expressing the MLS_B
233 constitutive phenotype. Three studies using an experimental model of aortic endocarditis in
234 rabbit or in rat indicated decreased *in vivo* efficacy of quinupristin-dalfopristin against MLS_B-
235 resistant strains of *S. aureus* and *E. faecium* [72–74]. In one study, failure was imputed to the
236 short plasmatic half-life of dalfopristin, highlighting the importance of the individual kinetics
237 of each component of the combination [74]. Another study showed a maintained *in vivo*
238 efficacy of quinupristin-dalfopristin against a *S. aureus* strain constitutively expressing an
239 *erm(A)* gene [75]. Unfortunately, no large clinical studies are available to provide a definitive
240 answer.

241 When strains express the inducible MLS_B phenotype, they remain susceptible to
242 clindamycin and type B streptogramins. However, concern over the possibility of selection of
243 constitutive mutants resistant to clindamycin during therapy has led to discourage clinicians
244 from prescribing streptogramin antibiotics. Similarly, the capacity of type B streptogramins to
245 select constitutively resistant mutants was described [70]. However, the emergence of mutants

1
2
3 246 was prevented *in vitro* if the cultures were exposed to type A streptogramins, suggesting that
4
5 247 such mutants were unlikely to be selected *in vivo* when applying the streptogramin
6
7
8 248 combination [70].

9 10 249 **7. Epidemiology of resistance**

11
12 250 Although rare, resistance to streptogramins has been reported in *E. faecium* isolates
13
14 251 recovered from patients treated with quinupristin-dalfopristin [49,76]. This resistance was
15
16 252 associated with clinical failure and persistent VREF infections in almost all cases [49]. Other
17
18 253 streptogramin-resistant *E. faecium* isolates have also been recovered from humans in Europe
19
20 254 and in the US [77]. The rate of resistance to quinupristin-dalfopristin is usually $\leq 10\%$ but
21
22 255 higher rates have been reported in Europe (up to 30%) [78–80]. A major concern is the
23
24 256 resistance among *E. faecium* isolates from animal sources that appears to be more common
25
26 257 (up to 100%) [49]. This is likely related to the extensive use of streptogramins in animal
27
28 258 husbandry (as growth factors) and veterinary medicine [16]. Whereas virginiamycin is still
29
30 259 approved by the US FDA to promote growth and prevent or control disease in chickens,
31
32 260 turkeys, swine, and cattle, it has been banned since 1999 in Europe [16]. The emergence of
33
34 261 streptogramin-resistant *E. faecium* isolates seems to be substantially the result of
35
36 262 virginiamycin use in animals and the transfer of streptogramin resistance via food to humans
37
38 263 [49,81]. In staphylococci (MRSA and CoNS), prevalence of resistance to quinupristin-
39
40 264 dalfopristin remains very low ($< 1\%$) [82].

41
42 265 Despite the longstanding oral use of streptogramins in France, the frequency of resistance
43
44 266 to pristinamycin remains low in *S. aureus* and CoNS (usually $< 5\text{--}10\%$) [83]. In North
45
46 267 America, resistance to quinupristin-dalfopristin has been infrequently observed, where more
47
48 268 than 98% of *S. aureus* (including CA-MRSA) and CoNS isolates are entirely susceptible
49
50 269 [44,78,79,84–86]. Although macrolide resistance in β -hemolytic streptococci is common,
51
52 270 high-level streptogramin resistance has not been reported yet. However, several *S. agalactiae*
53
54
55
56
57
58
59
60

1
2
3 271 isolates from New Zealand and USA expressed *lsa(C)* or *lsa(E)* genes and expressed LS_A
4
5 272 phenotype [87,88]. Among pneumococci and viridans streptococci, resistance to quinupristin-
6
7 273 dalfopristin is very uncommon, with more than 99% and 97% of susceptible strains,
8
9 274 respectively [84,86]. In France, all strains of *S. pneumoniae* isolated in adults and children
10
11 275 were susceptible to pristinamycin in 2016 [89].

14 276 **8. Pharmacokinetics and Pharmacodynamics**

16
17 277 The two main components of pristinamycin (i.e. PI_A and PII_A) exhibit nearly parallel
18
19 278 plasma kinetics (**Table 4**) [90]. They are both quite rapidly absorbed, especially with
20
21 279 concomitant food intake (t_{max} , 1 h vs. 3 h) [90]. Although few data on its metabolism are
22
23 280 available, pristinamycin is mainly eliminated in the bile and poorly penetrates into **cerebral**
24
25 281 **spinal fluid**. Only scarce data are available on the diffusion in other biological fluids and into
26
27 282 tissues, in particular bone.

28
29 283 Due to its minimal oral absorption, quinupristin-dalfopristin is only administered
30
31 284 intravenously, at a fixed 30:70 ratio. A linear relationship between dose and maximum plasma
32
33 285 concentration (C_{max}) has been observed [29,91]. The main pharmacokinetic parameters after a
34
35 286 single 7.5 mg/kg infusion over 1 h are shown in **Table 4** [29,91]. After multiple doses (7.5
36
37 287 mg/kg q8h or q12h), steady state is achieved by day 2 and there is an increase of ca. 20% in
38
39 288 C_{max} and AUC for both components [29,91]. Quinupristin exhibits higher, although moderate,
40
41 289 protein binding than dalfopristin (**Table 4**) [29,91]. Both quinupristin and dalfopristin
42
43 290 distribute well into tissues, such as kidneys, liver, spleen, salivary glands, and into white
44
45 291 blood cells, but the penetration into the CSF is poor [29,91]. Extravascular penetration into
46
47 292 blister fluid is approximately 40% of that of the plasma [29,91]. The diffusion of radiolabeled
48
49 293 quinupristin and dalfopristin, alone or in combination, in aortic vegetations from experimental
50
51 294 endocarditis in rabbits was also evaluated [92]. Quinupristin was homogeneously distributed
52
53 295 throughout the vegetations whereas dalfopristin showed a decreasing gradient of
54
55
56
57
58
59
60

1
2
3 296 concentration between the periphery and the core of the vegetation. Both compounds are
4
5 297 rapidly metabolized via non-enzymatic reactions [29,91]. Quinupristin is converted in two
6
7 298 active metabolites; a glutathione-conjugated compound (RP 69012) and a cysteine-conjugated
9
10 299 compound (RPR 100391) whereas dalfopristin is hydrolyzed to the natural pristinamycin II_A
11
12 300 (RP 12536). Importantly, these metabolites exhibit antibacterial activity similar to that of the
13
14 301 parental compounds. Quinupristin-dalfopristin is hepatically cleared and excreted through the
16
17 302 biliary tract (**Table 4**) [29,91]. Quinupristin and dalfopristin exhibit a biphasic elimination,
18
19 303 and distribution half-life ($t_{1/2}$) values of their metabolites are slightly longer ($\times 1.1-1.5$)
20
21 304 [29,91]. After administration of multiples doses, clearance of quinupristin-dalfopristin is
23
24 305 decreased by ca. 20%. Age, gender, and obesity appear to have no clinically significant
25
26 306 impact [29,91]. Finally, no dosage adjustments are necessary in patients with renal
27
28 307 impairment (including those under hemodialysis) and mild-to-moderate hepatic disease
30
31 308 [29,91]. The ratio AUC to MIC (AUC/MIC) seems to be the most predictive PK/PD
32
33 309 parameter of quinupristin-dalfopristin for antibacterial activity against *S. aureus* and *S.*
34
35 310 *pneumoniae* [91]. In addition, this association possesses an extended post-antibiotic effect
37
38 311 (PAE) against most of Gram-positive pathogens, which varies from approximately 4 to 5 h (at
39
40 312 4-fold MIC) in *S. aureus* and *S. epidermidis* [29]. At 4-fold MIC, a prolonged PAE is also
42
43 313 observed for *S. pneumoniae* (ca. 8 h), *S. pyogenes* (ca. 9-10 h), and *S. agalactiae* (ca. 7 h)
44
45 314 [29]. Finally, it has a PAE around 4-5 h (at 4-fold MIC) against *E. faecium*, even if it may be
46
47 315 as short as 0.2-1 h for some VREF strains [29,91].

49 316 **9. Clinical use**

51 317 Even if there are only a few randomized clinical trials to support the use of pristinamycin,
53
54 318 oral and topical preparations have been used in some European countries (particularly in
55
56 319 France) for more than 50 years, its efficacy has been largely demonstrated in humans
57
58 320 throughout this long period of time. In France, pristinamycin is primarily indicated for the
59
60

1
2
3 321 management of staphylococcal and streptococcal infections in adults (2-3 g/day) and children
4
5 322 (50 mg/kg/day): sinusitis, bronchopulmonary and skin infections. Two double-blind
6
7 323 randomized multicenter studies have demonstrated the non-inferiority of pristinamycin versus
8
9 324 cefuroxime axetil in the treatment of acute sinusitis in adults (**Table 5**) [93,94]. Two large
10
11 325 multicenter studies have also validated the use of pristinamycin in the treatment of
12
13 326 community-acquired pneumonia and another in **chronic obstructive pulmonary disease** acute
14
15 327 exacerbations (**Table 5**) [95–97]. A multicenter phase IV french study comparing the efficacy
16
17 328 of pristinamycin (2g x 2 per day for 2 days then 1g x 3 per day for 5 to 7 days) versus
18
19 329 amoxicillin (1g x 3 per day for 7 to 9 days) in adults with acute community acquired
20
21 330 pneumonia is currently undergoing (www.clinicaltrials.gov; NCT02332577). Several
22
23 331 prospective studies have also demonstrated that pristinamycin was a good alternative to treat
24
25 332 skins infections, such as erysipelas and superficial pyodermas (**Table 5**)[98–101].
26
27 333 Pristinamycin is not recommended as a first-line treatment for osteo-articular and bone joint
28
29 334 infections but several retrospective studies have described its clinical utility for (success rate
30
31 335 ca. 70%) [13,102,103]. Pristinamycin was also effective for MDR Gram-positive infections
32
33 336 treatment, especially MRSA (success rates ca. 80%) [102,104–106]. Several studies showed
34
35 337 that pristinamycin might be useful in management of *Mycoplasma genitalium* infections
36
37 338 [107,108]. Since 2016, European guidelines recommended to use pristinamycin as a third-line
38
39 339 treatment after azithromycin and moxifloxacin treatment failure for *M. genitalium* infections,
40
41 340 an important sexually transmitted pathogen responsible for both male and female genital tract
42
43 341 disease [40]. Finally, In 2016, Teng *et al.* demonstrated that pristinamycin was a good
44
45 342 alternative to treat infections due to resistant Gram-positive bacteria in patients with cancer
46
47 343 [14].

48
49 344 Quinupristin-dalfopristin was firstly investigated on an emergency-use basis in the
50
51 345 treatment of infections attributable to MDR Gram-positive bacteria, such as MRSA and
52
53
54
55
56
57
58
59
60

1
2
3 346 VREF [29]. Its efficacy in the treatment of MRSA infections was documented in case reports,
4
5 347 a comparative pilot study and two phase III studies, with clinical success rates consistently
6
7 348 higher than 60% (**Table 5**) [29,109]. In a small single-blind randomized study, quinupristin-
8
9 349 dalfopristin has been also found to achieve similar response rates to vancomycin for the
10
11 350 treatment of catheter-related bloodstream infections (**Table 5**) [110]. The efficacy of
12
13 351 quinupristin-dalfopristin in the treatment of VREF infections was determined in three large
14
15 352 prospective phase III studies, with clinical and bacteriological success rates between 50 and
16
17 353 70% (**Table 5**) [111–113]. The overall response rates varied according to the site of infection
18
19 354 (<45% for endocarditis, intra-abdominal and intravascular infections) [111]. It is important to
20
21 355 note that the treatment with quinupristin-dalfopristin may also favor an *E. faecalis*
22
23 356 superinfection, because of the antimicrobial spectrum of quinupristin-dalfopristin excluded *E.*
24
25 357 *faecalis* [111]. Two large randomized open multicenter trials have compared quinupristin-
26
27 358 dalfopristin with standard therapy in patients suffering from presumed Gram-positive
28
29 359 complicated skin and soft-tissue infections (SSSIs) with similar clinical and bacteriological
30
31 360 success rates in the two groups (**Table 5**) [29,114]. For the treatment of nosocomial
32
33 361 pneumonia, the efficacy of quinupristin-dalfopristin plus aztreonam versus vancomycin plus
34
35 362 aztreonam was tested in a randomized, non-blind, multicenter study, and the equivalence of
36
37 363 the two antimicrobial regimens was demonstrated (**Table 5**) [115]. Quinupristin-dalfopristin
38
39 364 was also used successfully to treat a variety of infections, such as cellulitis, catheter-related
40
41 365 bacteremia, osteomyelitis, peritonitis, septic arthritis/bursitis, and wound infections [29].
42
43 366 Finally, a single study has reported a clinical benefit (favorable clinical and microbiological
44
45 367 response rates at 69% and 78%, respectively) in pediatric patients with severe Gram-positive
46
47 368 infections [116]. Since 1999, the association quinupristin-dalfopristin is approved by the USA
48
49 369 FDA for complicated SSSIs caused by oxacillin-susceptible *S. aureus* and *S. pyogenes*. In
50
51 370 1999, quinupristin-dalfopristin was also approved for the treatment of severe infections due to
52
53
54
55
56
57
58
59
60

1
2
3 371 VREF associated with bacteremia, but approval was removed by USA FDA in 2010. In 2015,
4
5 372 European Society of Cardiology recommended to use quinupristin-dalfopristin to treat
6
7 373 infective endocarditis due to aminoglycosides, beta-lactams and vancomycin resistant *E.*
8
9 374 *faecium* [117]. The efficacy of the streptogramin combination in infections due to
10
11 375 clindamycin-resistant staphylococci (mostly hospital-acquired MRSA) remains controversial.
12
13 376 The recommended dosages of quinupristin-dalfopristin are 7.5 mg/kg every 12 h for
14
15 377 complicated SSTIs and 7.5 mg/kg every 8 h for VRE infections (IV infusion over 1 h).

16
17 378 Another oral streptogramin have been developed, named NXL103. Two multicenter,
18
19 379 randomized, phase II clinical trials have been conducted in 2007 and 2009 (Table 5). The first
20
21 380 one evaluated NXL103 efficacy, safety and tolerance for the treatment of community-
22
23 381 acquired pneumonia in adults (www.clinicaltrials.gov, NCT00653172). The second one
24
25 382 evaluated NXL103 to treat acute bacterial skin infections (www.clinicaltrials.gov,
26
27 383 NCT00949130). Those two studies were stopped in 2009 and 2010 respectively. No clinical
28
29 384 data has been published since then.

30
31
32
33
34
35 385

36 386 **10. Adverse effects and drug interactions**

37
38 387 Pristinamycin is generally well tolerated, with gastrointestinal disturbances (incidence ca.
39
40 388 7-25%) being the most frequent adverse events (nausea, vomiting, diarrhea), while some skin
41
42 389 rashes, arthralgia or myalgia have been also reported [13,94,118].

43
44 390 The two major adverse effects of quinupristin-dalfopristin are venous intolerance
45
46 391 (incidence>50%), and arthralgia or myalgia (incidence, 2-30%), which can be severe [39].
47
48 392 Administration of quinupristin-dalfopristin requires the presence of a central venous catheter
49
50 393 because of venous toxicity, which is an important limitation to its use [39]. Other common
51
52 394 adverse events (incidence, 2-4%) include nausea, vomiting, diarrhea, and rash [39].
53
54 395 Biologically, an elevation of conjugated bilirubin may be observed [39]. Quinupristin and
55
56
57
58
59
60

1
2
3 396 dalfopristin are inhibitors of CYP3A4 and consequently drug interaction is observed with
4
5 397 ciclosporin, midazolam, nifedipine, tamoxifen, and terfenadine [39,91].
6

7 398 **11. Conclusion**

9
10 399 Streptogramin antibiotics are a combination of chemically unrelated compounds, namely
11
12 400 type A and type B streptogramins, which act synergistically by inhibiting protein synthesis.
13
14 401 Although the streptogramin compounds are separately bacteriostatic, the combination usually
15
16 402 becomes bactericidal. Their spectrum of activity includes a broad range of aerobic and
17
18 403 anaerobic Gram-positive bacteria, but also most of fastidious Gram-negative and atypical
19
20 404 bacteria. This synergism also allows overcoming certain mechanisms of resistance to the
21
22 405 individual components of the combination and may explain low rates of resistance reported so
23
24 406 far. To date, two streptogramins are available in human medicine, oral pristinamycin, and
25
26 407 quinupristin-dalfopristin, an injectable formulation approved since 1999 and 2000 in the US
27
28 408 and Europe, respectively. **In this study we have synthesized all the clinical studies evaluating**
29
30 409 **these antibiotics.** Finally, virginiamycin, an oral streptogramin, was therapeutically used in
31
32 410 France until late 1990s and as a growth promoter for animals in many European countries
33
34 411 until early 2000s and currently in the US.
35
36
37
38
39
40 412
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 413 **Expert opinion**
4

5 414 Pristinamycin and quinupristin-dalfopristin are the two streptogramins used in human
6
7 415 medicine. They are a combination of two compounds that are bacteriostatic separately **but**
8
9 416 **have bactericidal activity when used synergistically**. The mechanism of the synergy is unique
10
11 417 and based on a stable ribosome conformational change provoked by the binding of
12
13 418 streptogramins A that unmasks a high-affinity binding site for streptogramins B. Using
14
15 419 combined antimicrobials to achieve synergism and enhance antimicrobial activity is not a new
16
17 420 concept. This notion has already proven to be correct for antimicrobial combinations
18
19 421 developed as a single drug such as trimethoprim combined with sulfamethoxazole
20
21 422 (cotrimoxazole), which sequentially inhibit two **different enzymatic** steps of the same
22
23 423 metabolic pathway (i.e. synthesis of folic acids). In addition, if the synergism is conserved
24
25 424 despite resistance to one of the components, this should avoid resistance to the combination.
26
27 425 The value of the synergy strategy has been highlighted by the maintained **in vitro** activity of
28
29 426 the streptogramin combination against most strains that are resistant to either type of
30
31 427 streptogramins and by the low frequency of resistant isolates in France despite the use of
32
33 428 pristinamycin for more than 50 years.
34
35
36
37
38

39 429 Nonetheless, an important issue for clinical use of streptogramins is the specific
40
41 430 pharmacokinetics of each component of the combination that needs to reach the bacterial
42
43 431 pathogen at the site of infection in a ratio allowing synergism. This is particularly true for
44
45 432 strains that are resistant to one of the streptogramin components.
46
47
48

49 433 Pristinamycin is mainly used in France until now to treat sinusitis, bronchopulmonary and
50
51 434 skin infections due to streptococci or staphylococci. This antibiotic is easy to use because of
52
53 435 its non-invasive route of administration, oral or topical. In addition, pristinamycin is well
54
55 436 tolerated with few side effects; it also has few interactions with other drugs and is
56
57 437 inexpensive. **Currently, pristinamycin is recommended to treat sinusitis, bronchopulmonary**
58
59
60

1
2
3 438 infections and skin infections due to streptococci or staphylococci. *M. genitalium* is an
4
5 439 important sexually transmitted pathogen responsible for both male and female genital tract
6
7 440 disease. Recently, the interest of pristinamycin in the treatment of infections due to this
8
9 441 pathogen have been demonstrated and European guidelines recommend to use pristinamycin
10
11 442 as a third-line treatment after azithromycin and moxifloxacin treatment failure for *M.*
12
13 443 *genitalium* infections. Moreover, this antibiotic has been described to be a good alternative to
14
15 444 treat infections due to resistant Gram-positive bacteria in patients with cancer in an Australian
16
17 445 study.

21 446 Quinupristin-dalfopristin, an injectable streptogramin, was the first to be developed
22
23 447 internationally. Despite its effectiveness in the treatment of severe Gram-positive bacterial
24
25 448 infections demonstrated in several studies, and the low rate of reported resistance, the
26
27 449 penetration of this molecule into the antibiotic market has remained limited. This can be
28
29 450 probably explained in part by the mode of administration, which requires a central venous
30
31 451 catheter. The low use of this antibiotic can likely also be explained by the high prevalence of
32
33 452 side effects, namely venous intolerance and the risk of thrombophlebitis. Studies to decrease
34
35 453 the toxicity of this molecule would be interesting, in order to make it more accessible and
36
37 454 easy to use. Currently marketed in North America, its high cost also represents a barrier to its
38
39 455 use.

44 456

47 457 **Financial & competing interests disclosure**

48
49 458 The authors have no other relevant affiliations or financial involvement with any
50
51 459 organization or entity with a financial interest in or financial conflict with the subject matter
52
53 460 or materials discussed in the manuscript.

54
55 461 No writing assistance was utilized in the production of this manuscript.

56
57 462

1
2
3 463 **Key issues**
4

- 5 464
- 6 • Streptogramins are a bactericidal combination of two compounds, streptogramins A
7 and B that act synergistically by inhibition of bacterial protein synthesis.
8 465
 - 9 • Two streptogramins (pristinamycin and quinupristin-dalfopristin) are currently used in
10 human medicine.
11 466
 - 12 • Streptogramins exhibit a rapid bactericidal activity against a wide range of Gram-
13 positive bacteria (including multidrug-resistant isolates)
14 467
 - 15 • Several mechanisms of resistance have been identified in staphylococci and
16 enterococci but their prevalence among clinical isolates remains very low
17 468
 - 18 • The efficacy of pristinamycin has been largely demonstrated due to its extensive use
19 for 50 years in France and some African countries.
20 469
 - 21 • The clinical use quinupristin-dalfopristin has remained limited, mainly due to its poor
22 tolerance
23 470
 - 24 • Streptogramins (especially pristinamycin) can be considered as potential alternatives
25 for the treatment of Gram-positive infections
26 471
- 27 472
28 473
29 474
30 475
31 476
32 477
33 478
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

479 **References**

- 480 [1] Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a
481 review of the global challenge. *J Infect.* 2009;59 Suppl 1:S4-16.
- 482 [2] David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus*
483 *aureus*: epidemiology and clinical consequences of an emerging epidemic. *Clin*
484 *Microbiol Rev.* 2010;23:616–87.
- 485 [3] Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic Review and meta-analysis of the
486 epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-
487 Intermediate *Staphylococcus aureus* Isolates. *PloS One.* 2015;10:e0136082.
- 488 [4] Berlak N, Shany E, Ben-Shimol S, et al. Late onset sepsis: comparison between
489 coagulase-negative staphylococci and other bacteria in the neonatal intensive
490 care unit. *Infect Dis.* 2018;0:1–7.
- 491 [5] Bor DH, Woolhandler S, Nardin R, Bruschi J, Himmelstein DU. Infective
492 Endocarditis in the U.S., 1998–2009: A Nationwide Study. *PLOS ONE.*
493 2013;8:e60033.
- 494 [6] von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-
495 negative staphylococci. *Lancet Infect Dis.* 2002;2:677–85.
- 496 [7] O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections:
497 epidemiology, clinical manifestations, and optimal management. *Infect Drug*
498 *Resist.* 2015;8:217–30.
- 499 [8] Wantuch PL, Avci FY. Current status and future directions of invasive
500 pneumococcal diseases and prophylactic approaches to control them. *Hum*
501 *Vaccines Immunother.* 2018;0:1–19.
- 502 [9] Chochua S, Metcalf BJ, Li Z, et al. Invasive serotype 35B pneumococci including an
503 expanding serotype switch lineage, United States, 2015-2016. *Emerg Infect Dis.*
504 2017;23:922–30.
- 505 [10] Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new
506 century. *Expert Opin Investig Drugs.* 2010;19:215–34.
- 507 [11] Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? *Int J*
508 *Antimicrob Agents.* 2009;34:15–20.
- 509 [12] Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for
510 Gram-positive bacteria. *Clin Microbiol Infect.* 2017;23:697–703.
- 511 [13] Cooper EC, Curtis N, Cranswick N, Gwee A. Pristinamycin: old drug, new tricks? *J*
512 *Antimicrob Chemother.* 2014;69:2319–25.
- 513 [14] Teng JC, Lingaratnam SM, Trubiano JA, Thursky KA, Slavin MA, Worth LJ. Oral
514 pristinamycin for the treatment of resistant Gram-positive infections in patients

- 1
2
3 515 with cancer: Evaluation of clinical outcomes. *Int J Antimicrob Agents*.
4 516 2016;47:391–6.
5
- 6 517 **[15] Politano AD, Sawyer RG. NXL-103, a combination of flopristin and**
7 **linopristin, for the potential treatment of bacterial infections including**
8 **community-acquired pneumonia and MRSA. *Curr Opin Investig Drugs Lond***
9 **Engl 2000. 2010;11:225–36. ***
10 520
11
- 12 521 *** Study about the NXL103, the last oral streptogramin developed**
13 522
14 523 **[16] Mast Y, Wohlleben W. Streptogramins – Two are better than one! *Int J Med***
15 **Microbiol. 2014;304:44–50. ***
16 524
17
- 18 525 *** Most recent complete review on streptogramin biosynthesis and its regulation**
19 526
20 527 [17] Bischoff KM, Zhang Y, Rich JO. Fate of virginiamycin through the fuel ethanol
21 528 production process. *World J Microbiol Biotechnol*. 2016;32:76.
22
- 23 529 [18] Mukhtar TA, Wright GD. Streptogramins, oxazolidinones, and other inhibitors of
24 530 bacterial protein synthesis. *Chem Rev*. 2005;105:529–42.
25
- 26 531 [19] Barrière JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, Desnottes JF. Recent
27 532 developments in streptogramin research. *Curr Pharm Des*. 1998;4:155–80.
28
- 29 533 [20] Canu A, Leclercq R. Overcoming bacterial resistance by dual target inhibition: the
30 534 case of streptogramins. *Curr Drug Targets Infect Disord*. 2001;1:215–25.
31
- 32 535 [21] Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: mode of action
33 536 and resistance. *Curr Drug Targets*. 2002;3:335–44.
34
- 35 537 [22] Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis
36 538 by streptogramins and related antibiotics. *J Antimicrob Chemother*. 1997;39
37 539 Suppl A:7–13.
38
- 39 540 [23] Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides.
40 541 *Drugs*. 1996;51 Suppl 1:20–30.
41
- 42 542 [24] Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics.
43 543 *Nat Rev Microbiol*. 2005;3:870–881.
44
- 45 544 [25] Hansen JL, Moore PB, Steitz TA. Structures of five antibiotics bound at the
46 545 peptidyl transferase center of the large ribosomal subunit. *J Mol Biol*.
47 546 2003;330:1061–75.
48
- 49 547 [26] Harms JM, Schlünzen F, Fucini P, Bartels H, Yonath A. Alterations at the peptidyl
50 548 transferase centre of the ribosome induced by the synergistic action of the
51 549 streptogramins dalfoipristin and quinupristin. *BMC Biol*. 2004;2:4.
52
- 53 550 [27] Tu D, Blaha G, Moore PB, Steitz TA. Structures of MLSBK antibiotics bound to
54 551 mutated large ribosomal subunits provide a structural explanation for resistance.
55 552 *Cell*. 2005;121:257–70.
56
57
58
59
60

- 1
2
3 553 [28] Bouanchaud DH. *In-vitro* and *in-vivo* antibacterial activity of
4 554 quinupristin/dalfopristin. J Antimicrob Chemother. 1997;39 Suppl A:15–21.
5
6 555 [29] Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in
7 556 the management of serious gram-positive infections. Drugs. 1999;58:1061–97.
8
9
10 557 [30] Speciale A, La Ferla K, Caccamo F, Nicoletti G. Antimicrobial activity of
11 558 quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-
12 559 positive spectrum. Int J Antimicrob Agents. 1999;13:21–8.
13
14 560 [31] Pankuch GA, Kelly LM, Lin G, et al. Activities of a new oral streptogramin, XRP
15 561 2868, compared to those of other agents against *Streptococcus pneumoniae* and
16 562 haemophilus species. Antimicrob Agents Chemother. 2003;47:3270–4.
17
18
19 563 [32] Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC. *In vitro* activity of an
20 564 oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
21 565 Antimicrob Agents Chemother. 2005;49:3034–9.
22
23 566 [33] Goldstein EJC, Citron DM, Merriam CV, et al. Comparative in vitro activities of XRP
24 567 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin,
25 568 linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against
26 569 anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob
27 570 Agents Chemother. 2005;49:408–13.
28
29
30 571 [34] Low DE, Nadler HL. A review of in-vitro antibacterial activity of
31 572 quinupristin/dalfopristin against methicillin-susceptible and -resistant
32 573 *Staphylococcus aureus*. J Antimicrob Chemother. 1997;39 Suppl A:53–8.
33
34
35 574 [35] Singh KV, Weinstock GM, Murray BE. An *Enterococcus faecalis* ABC homologue
36 575 (Lsa) is required for the resistance of this species to clindamycin and
37 576 quinupristin-dalfopristin. Antimicrob Agents Chemother. 2002;46:1845–50.
38
39 577 [36] Singh KV, Murray BE. Differences in the *Enterococcus faecalis* lsa locus that
40 578 influence susceptibility to quinupristin-dalfopristin and clindamycin. Antimicrob
41 579 Agents Chemother. 2005;49:32–9.
42
43
44 580 [37] Dina J, Malbruny B, Leclercq R. Nonsense mutations in the lsa-like gene in
45 581 *Enterococcus faecalis* isolates susceptible to lincosamides and Streptogramins A.
46 582 Antimicrob Agents Chemother. 2003;47:2307–9.
47
48 583 [38] Bonfiglio G, Furneri PM. Novel streptogramin antibiotics. Expert Opin Investig
49 584 Drugs. 2001;10:185–98.
50
51 585 [39] Delgado G, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin-dalfopristin:
52 586 an overview. Pharmacotherapy. 2000;20:1469–85.
53
54
55 587 [40] **Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on**
56 588 ***Mycoplasma genitalium* infections. J Eur Acad Dermatol Venereol JEADV.**
57 589 **2016;30:1650–6.***
58
59
60 590 *** Pristinamycin could be used to treat *Mycoplasma genitalium* infections.**

- 1
2
3 591 [41] Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin
4 592 failure in a *Mycoplasma genitalium*-infected cohort and response of azithromycin
5 593 failures to alternative antibiotic regimens. Clin Infect Dis Off Publ Infect Dis Soc
6 594 Am. 2015;60:1228–36.
- 8
9 595 [42] Clinical and Laboratory Standards Institute MP. Performance standards for
10 596 antimicrobial susceptibility testing, M100. 28th ed. S.l.: Clinical and Laboratory
11 597 Standards Institute; 2018.
- 13 598 [43] Clarebout G, Nativelle E, Bozdogan B, Villers C, Leclercq R. Bactericidal activity of
14 599 quinupristin-dalfopristin against strains of *Staphylococcus aureus* with the
15 600 MLS(B) phenotype of resistance according to the *erm* gene type. Int J Antimicrob
16 601 Agents. 2004;24:444–9.
- 19 602 [44] John MA, Pletch C, Hussain Z. *In vitro* activity of quinupristin/dalfopristin,
20 603 linezolid, telithromycin and comparator antimicrobial agents against 13 species
21 604 of coagulase-negative staphylococci. J Antimicrob Chemother. 2002;50:933–8.
- 23 605 [45] Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin
24 606 against *Staphylococcus aureus*: clindamycin susceptibility as a surrogate
25 607 indicator. Antimicrob Agents Chemother. 2000;44:2880–2.
- 28 608 [46] Brown J, Freeman BB. Combining Quinupristin/Dalfopristin with Other Agents
29 609 for Resistant Infections. Ann Pharmacother. 2004;38:677–85.
- 31 610 [47] Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-
32 611 dalfopristin combined with other antibiotics against vancomycin-resistant
33 612 enterococci. Antimicrob Agents Chemother. 2002;46:1319–24.
- 36 613 [48] Schwarz S, Shen J, Kadlec K, et al. Lincosamides, Streptogramins, phenicols, and
37 614 pleuromutilins: mode of action and mechanisms of resistance. Cold Spring Harb
38 615 Perspect Med. 2016;6.
- 40 616 [49] Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-
41 617 dalfopristin resistance in gram-positive bacteria: mechanism of resistance and
42 618 epidemiology. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38:92–8.
- 45 619 [50] Roberts MC. Environmental macrolide-lincosamide-streptogramin and
46 620 tetracycline resistant bacteria. Front Microbiol. 2011;2:40.
- 48 621 [51] Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and
49 622 oxazolidinone resistance genes. FEMS Microbiol Lett. 2008;282:147–59.
- 51 623 [52] Hays C, Lienhard R, Auzou M, et al. Erm(X)-mediated resistance to macrolides,
52 624 lincosamides and streptogramins in *Actinobaculum schaalii*. J Antimicrob
53 625 Chemother. 2014;69:2056–60.
- 56 626 [53] Wipf JRK, Schwendener S, Perreten V. The novel macrolide-lincosamide-
57 627 streptogramin B resistance gene *erm*(44) is associated with a prophage in
58 628 *Staphylococcus xylosus*. Antimicrob Agents Chemother. 2014;58:6133–8.
- 60

- 1
2
3 629 [54] Wipf JRK, Schwendener S, Nielsen JB, Westh H, Perreten V. The new macrolide-
4 630 lincosamide-streptogramin B resistance gene erm(45) is located within a
5 631 genomic island in *Staphylococcus fleurettii*. *Antimicrob Agents Chemother.*
6 632 2015;59:3578–81.
- 8
9 633 [55] Wipf JRK, Riley MC, Kania SA, et al. New Macrolide-Lincosamide-Streptogramin B
10 634 resistance gene erm(48) on the novel plasmid pJW2311 in *Staphylococcus*
11 635 *xylosus*. *Antimicrob Agents Chemother.* 2017;61.
- 13 636 [56] Cattoir V, Merabet L, Legrand P, Soussy C-J, Leclercq R. Emergence of a
14 637 *Streptococcus pneumoniae* isolate resistant to streptogramins by mutation in
15 638 ribosomal protein L22 during pristinamycin therapy of pneumococcal
16 639 pneumonia. *J Antimicrob Chemother.* 2007;59:1010–2.
- 18
19 640 [57] Sharkey LKR, Edwards TA, O'Neill AJ. ABC-F Proteins mediate antibiotic
20 641 resistance through ribosomal protection. *mBio.* 2016;7:e01975.
- 22 642 [58] Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes fexA and cfr
23 643 among chloramphenicol-resistant *Staphylococcus* isolates. *Antimicrob Agents*
24 644 *Chemother.* 2006;50:1156–63.
- 26
27 645 [59] Wang Y, Zhang W, Wang J, et al. Distribution of the multidrug resistance gene cfr
28 646 in *Staphylococcus* species isolates from swine farms in China. *Antimicrob Agents*
29 647 *Chemother.* 2012;56:1485–90.
- 31 648 [60] He T, Wang Y, Schwarz S, Zhao Q, Shen J, Wu C. Genetic environment of the multi-
32 649 resistance gene cfr in methicillin-resistant coagulase-negative staphylococci from
33 650 chickens, ducks, and pigs in China. *Int J Med Microbiol IJMM.* 2014;304:257–61.
- 35
36 651 [61] Toh S-M, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders
37 652 a clinical strain of methicillin-resistant *Staphylococcus aureus* resistant to the
38 653 synthetic antibiotic linezolid. *Mol Microbiol.* 2007;64:1506–14.
- 40
41 654 [62] Witte W, Cuny C. Emergence and spread of cfr-mediated multiresistance in
42 655 staphylococci: an interdisciplinary challenge. *Future Microbiol.* 2011;6:925–31.
- 43
44 656 [63] Cai JC, Hu YY, Zhou HW, Chen G-X, Zhang R. Dissemination of the same cfr-
45 657 carrying plasmid among methicillin-resistant *Staphylococcus aureus* and
46 658 coagulase-negative staphylococcal isolates in China. *Antimicrob Agents*
47 659 *Chemother.* 2015;59:3669–71.
- 49
50 660 [64] Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A new mechanism for
51 661 chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S
52 662 ribosomal RNA at A2503. *Mol Microbiol.* 2005;57:1064–73.
- 53
54 663 [65] Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA
55 664 methyltransferase confers resistance to Phenicol, Lincosamides, Oxazolidinones,
56 665 Pleuromutilins, and Streptogramin A antibiotics. *Antimicrob Agents Chemother.*
57 666 2006;50:2500–5.
- 59
60

- 1
2
3 667 [66] Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne
4 668 chloramphenicol-florfenicol resistance gene in *Staphylococcus sciuri*. Antimicrob
5 669 Agents Chemother. 2000;44:2530–3.
- 7 670 [67] Murina V, Kasari M, Hauryliuk V, Atkinson GC. Antibiotic resistance ABCF
8 671 proteins reset the peptidyl transferase centre of the ribosome to counter
9 672 translational arrest. Nucleic Acids Res. 2018;46:3753–63.
- 12 673 [68] Isnard C, Malbruny B, Leclercq R, Cattoir V. Genetic basis for in vitro and *in vivo*
13 674 resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP
14 675 phenotype) in *Enterococcus faecium*. Antimicrob Agents Chemother.
15 676 2013;57:4463–9.
- 18 677 [69] El Solh N, Allignet J. Staphylococcal resistance to streptogramins and related
19 678 antibiotics. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother.
20 679 1998;1:169–75.
- 22 680 [70] Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral
23 681 semisynthetic streptogramin, against staphylococci with various mechanisms of
24 682 resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob
25 683 Chemother. 1992;30 Suppl A:67–75.
- 28 684 [71] Dupuis M, Leclercq R. Activity of a new oral streptogramin, XRP2868, against
29 685 gram-positive cocci harboring various mechanisms of resistance to
30 686 streptogramins. Antimicrob Agents Chemother. 2006;50:237–42.
- 32 687 [72] Fantin B, Leclercq R, Merlé Y, et al. Critical influence of resistance to
33 688 streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-
34 689 dalfopristin) in experimental endocarditis due to *Staphylococcus aureus*.
35 690 Antimicrob Agents Chemother. 1995;39:400–5.
- 38 691 [73] Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to
39 692 macrolides, lincosamides, and streptogramin B-type antibiotics in *Enterococcus*
40 693 *faecium* on activity of quinupristin-dalfopristin in vitro and in rabbits with
41 694 experimental endocarditis. Antimicrob Agents Chemother. 1997;41:931–5.
- 44 695 [74] Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental
45 696 endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant
46 697 *Staphylococcus aureus* with RP 59500. Antimicrob Agents Chemother.
47 698 1995;39:1419–24.
- 49 699 [75] Batard E, Jacqueline C, Boutoille D, et al. Combination of quinupristin-dalfopristin
50 700 and gentamicin against methicillin-resistant *Staphylococcus aureus*: experimental
51 701 rabbit endocarditis study. Antimicrob Agents Chemother. 2002;46:2174–8.
- 54 702 [76] Wang S, Guo Y, Lv J, et al. Characteristic of *Enterococcus faecium* clinical isolates
55 703 with quinupristin/dalfopristin resistance in China. BMC Microbiol. 2016;16:246.
- 57 704 [77] Thal LA, Zervos MJ. Occurrence and epidemiology of resistance to virginiamycin
58 705 and streptogramins. J Antimicrob Chemother. 1999;43:171–6.
- 59
60

- 1
2
3 706 [78] Saravolatz LD, Eliopoulos GM. Quinupristin-Dalfopristin and linezolid: evidence
4 707 and opinion. Clin Infect Dis. 2003;36:473–81.
5
6 708 [79] Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity
7 709 tested against methicillin-resistant staphylococci and vancomycin-resistant
8 710 enterococci isolated in European medical centers (2005). BMC Infect Dis.
9 711 2007;7:29.
10
11
12 712 [80] Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial
13 713 resistance and molecular epidemiology of vancomycin-resistant enterococci
14 714 from North America and Europe: a report from the SENTRY antimicrobial
15 715 surveillance program. Diagn Microbiol Infect Dis. 2007;58:163–70.
16
17
18 716 [81] Werner G, Klare I, Witte W. Molecular analysis of streptogramin resistance in
19 717 enterococci. Int J Med Microbiol IJMM. 2002;292:81–94.
20
21 718 [82] Shariati A, Dadashi M, Chegini Z, et al. The global prevalence of daptomycin,
22 719 tigecycline, quinupristin/dalfopristin, and linezolid-resistant *Staphylococcus*
23 720 *aureus* and coagulase-negative staphylococci strains: a systematic review and
24 721 meta-analysis. Antimicrob Resist Infect Control. 2020;9:56.
25
26
27 722 [83] Leclercq R, Soussy CJ, Weber P, Moniot-Ville N, Dib C, Groupe d'Etude
28 723 Multicentrique. [In vitro activity of the pristinamycin against the isolated
29 724 staphylococci in the french hospitals in 1999-2000]. Pathol Biol (Paris).
30 725 2003;51:400–4.
31
32
33 726 [84] Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-
34 727 spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone,
35 728 piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci:
36 729 report from the SENTRY antimicrobial surveillance program (North America:
37 730 2001-2002). Diagn Microbiol Infect Dis. 2003;47:435–40.
38
39
40 731 [85] Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of
41 732 tigecycline against community-acquired methicillin-resistant *Staphylococcus*
42 733 *aureus* isolates recovered from North American medical centers. Diagn Microbiol
43 734 Infect Dis. 2008;60:433–6.
44
45 735 [86] Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER
46 736 surveillance program results for 2010: an activity and spectrum analysis of
47 737 linezolid using 6801 clinical isolates from the United States (61 medical centers).
48 738 Diagn Microbiol Infect Dis. 2012;74:54–61.
49
50
51 739 [87] Malbruny B, Werno AM, Anderson TP, Murdoch DR, Leclercq R. A new phenotype
52 740 of resistance to lincosamide and streptogramin A-type antibiotics in
53 741 *Streptococcus agalactiae* in New Zealand. J Antimicrob Chemother.
54 742 2004;54:1040–4.
55
56 743 [88] Hawkins PA, Law CS, Metcalf BJ, et al. Cross-resistance to lincosamides,
57 744 streptogramins A and pleuromutilins in *Streptococcus agalactiae* isolates from
58 745 the USA. J Antimicrob Chemother. 2017;72:1886–92.
59
60

- 1
2
3 746 [89] Batah J, Varon E. Rapport d'activité 2017 du Centre National de Référence des
4 747 Pneumocoques. 2017;84.
5
6 748 [90] Koechlin C, Kempf JF, Jehl F, Monteil H. Single oral dose pharmacokinetics of the
7 749 two main components of pristinamycin in humans. *J Antimicrob Chemother.*
8 750 1990;25:651–6.
9
10 751 [91] Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. *Clin*
11 752 *Pharmacokinet.* 2004;43:239–52.
12
13
14 753 [92] Fantin B, Leclercq R, Ottaviani M, et al. In vivo activities and penetration of the
15 754 two components of the streptogramin RP 59500 in cardiac vegetations of
16 755 experimental endocarditis. *Antimicrob Agents Chemother.* 1994;38:432–7.
17
18
19 756 [93] Pessey JJ. [Pristinamycin use in the treatment of acute maxillary sinusitis in
20 757 adults]. *Med Mal Infect.* 2008;38:9–11.
21
22 758 [94] **Gehanno P, Berche P, Hercot O, et al. [Efficiency of a four-day course of**
23 759 **pristinamycin compared to a five-day course of cefuroxime axetil for acute**
24 760 **bacterial maxillary sinusitis in adult outpatients]. *Med Mal Infect.***
25 761 **2004;34:293–302. ***
26
27
28 762 *** The study evaluate pristinamycin in acute sinusitis, a frequent indication of**
29 763 **streptogramin use**
30 764
31 765 [95] Trémolières F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E. [Efficacy and
32 766 safety of pristinamycin vs amoxicillin in community acquired pneumonia in
33 767 adults]. *Pathol Biol (Paris).* 2005;53:503–10.
34
35
36 768 [96] Poirier R, Chardon H, Beraud A, et al. [Efficacy and tolerability of pristinamycin
37 769 vs amoxicillin-clavulanic acid combination in the treatment of acute community-
38 770 acquired pneumonia in hospitalized adults]. *Rev Pneumol Clin.* 1997;53:325–31.
39
40
41 771 [97] Léophonte P, Chidiac C, Drugeon HB, et al. [Treatment of exacerbations of chronic
42 772 obstructive pulmonary disease with pristinamycin]. *Rev Mal Respir.*
43 773 2004;21:261–71.
44
45 774 [98] Bernard P, Vaillant L, Martin C, Beylot C, Quentin R, Touron D. [Pristinamycin
46 775 versus oxacillin in the treatment of superficial pyoderma. A multicenter
47 776 randomized study in 293 outpatients]. *Ann Dermatol Venereol.* 1997;124:384–9.
48
49
50 777 [99] Bernard P, Chosidow O, Vaillant L, French Erysipelas Study Group. Oral
51 778 pristinamycin versus standard penicillin regimen to treat erysipelas in adults:
52 779 randomised, non-inferiority, open trial. *BMJ.* 2002;325:864.
53
54 780 [100] Bernard P, Risse L, Bonnetblanc JM. [Pristinamycin in the treatment of acute
55 781 bacterial dermohypodermatitis in adults. An open study of 42 patients]. *Ann*
56 782 *Dermatol Venereol.* 1996;123:16–20.
57
58
59
60

- 1
2
3 783 [101] Chosidow O, Bernard P, Berbis P, et al. Cloxacillin versus pristinamycin for
4 784 superficial pyodermas: a randomized, open-label, non-inferiority study. *Dermatol*
5 785 *Basel Switz.* 2005;210:370–4.
- 7 786 [102] Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular
8 787 infections due to methicillin-resistant *Staphylococcus aureus* (MRSA) and other
9 788 *Staphylococcus* spp. *J Antimicrob Chemother.* 2005;55:1008–12.
- 12 789 [103] Valour F, Boibieux A, Karsenty J, et al. Pristinamycin in the treatment of MSSA
13 790 bone and joint infection. *J Antimicrob Chemother.* 2016;71:1063–70.
- 15 791 [104] Reid AB, Daffy JR, Stanley P, Buising KL. Use of pristinamycin for infections by
16 792 gram-positive bacteria: clinical experience at an Australian hospital. *Antimicrob*
17 793 *Agents Chemother.* 2010;54:3949–52.
- 20 794 [105] Ruparelia N, Atkins BL, Hemingway J, Berendt AR, Byren I. Pristinamycin as
21 795 adjunctive therapy in the management of Gram-positive multi-drug resistant
22 796 organism (MDRO) osteoarticular infection. *J Infect.* 2008;57:191–7.
- 24 797 [106] Dancer SJ, Robb A, Crawford A, Morrison D. Oral streptogramins in the
25 798 management of patients with methicillin-resistant *Staphylococcus aureus* (MRSA)
26 799 infections. *J Antimicrob Chemother.* 2003;51:731–5.
- 29 800 [107] Bradshaw CS, Jensen JS, Waites KB. New horizons in *Mycoplasma genitalium*
30 801 treatment. *J Infect Dis.* 2017;216:S412–S419.
- 32 802 [108] Sethi S, Zaman K, Jain N. *Mycoplasma genitalium* infections: current treatment
33 803 options and resistance issues. *Infect Drug Resist.* 2017;10:283–292.
- 35 804 [109] Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment
36 805 of methicillin-resistant *Staphylococcus aureus* infections with quinupristin-
37 806 dalfopristin in patients intolerant of or failing prior therapy. For the Synercid
38 807 Emergency-Use Study Group. *J Antimicrob Chemother.* 2000;46:775–84.
- 41 808 [110] Raad I, Bompert F, Hachem R. Prospective, randomized dose-ranging open phase
42 809 II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of
43 810 catheter-related staphylococcal bacteremia. *Eur J Clin Microbiol Infect Dis Off*
44 811 *Publ Eur Soc Clin Microbiol.* 1999;18:199–202.
- 47 812 [111] Linden PK, Moellering RC, Wood CA, et al. Treatment of vancomycin-resistant
48 813 *Enterococcus faecium* infections with quinupristin/dalfopristin. *Clin Infect Dis Off*
49 814 *Publ Infect Dis Soc Am.* 2001;33:1816–23.
- 51 815 [112] Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing
52 816 quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant
53 817 *Enterococcus faecium* infections. *J Antimicrob Chemother.* 2004;53:646–9.
- 56 818 [113] Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompert F, Talbot GH. The
57 819 efficacy and safety of quinupristin/dalfopristin for the treatment of infections
58 820 caused by vancomycin-resistant *Enterococcus faecium*. *Synercid Emergency-Use*
59 821 *Study Group. J Antimicrob Chemother.* 1999;44:251–61.

- 1
2
3 822 [114] Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients
4 823 with complicated gram-positive skin and skin structure infections: two
5 824 randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin,
6 825 oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. *J*
7 826 *Antimicrob Chemother.* 1999;44:263–73.
- 8
9
10 827 [115] Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial
11 828 pneumonia. Prospective randomized comparison of quinupristin/dalfopristin
12 829 versus vancomycin. Nosocomial Pneumonia Group. *Am J Respir Crit Care Med.*
13 830 2000;161:753–62.
- 14
15 831 [116] Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of
16 832 quinupristin/dalfopristin for treatment of invasive Gram-positive infections in
17 833 pediatric patients. *Pediatr Infect Dis J.* 2002;21:950–6.
- 18
19
20 834 [117] Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management
21 835 of infective endocarditis. *Eur Heart J.* 2015;36:3075–128.
- 22
23 836 [118] Denis Prevot M, Thillard EM, Walther J, et al. Pristinamycin-induced arthralgia
24 837 and myalgia: Analysis of the French Pharmacovigilance Database. *Med Mal Infect.*
25 838 2018;48:58–62.
- 26
27
28 839
29
30 840
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 841 **Legends of the figures**
4

5 842 **Figure 1.** Structure of streptogramins A (right) and B (left).
6

7 843
8 844 **Figure 2.** Mechanism of action of streptogramins. (A) Normal protein elongation; attachment
9 845 of tRNAs to the peptidyl transferase center (PTC) and elongation of polypeptide chain. Then,
10 846 the peptide exits through the peptide exit tunnel. (B) Streptogramins could blocked tRNA
11 847 attachment and prevent early steps of elongation, or interact with the peptide exit tunnel.
12 848

13 849 **Figure 3.** Mechanisms of resistance to streptogramins A and B
14 850
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

161x150mm (300 x 300 DPI)




Figure 2

338x190mm (96 x 96 DPI)




Figure 3

338x190mm (96 x 96 DPI)

Table 1: Examples of streptogramins [19,20].

Streptogramins	Individual components		Producing organism
	A	B	
Natural products			
Madumycin	Madumycin II	Madumycin I	<i>Actinomadura flava</i>
Mikamycin	Mikamycin A	Mikamycin B	<i>Streptomyces mitakaensis</i>
Pristinamycin	Pristinamycin II _A , II _B , II _C , II _D , II _E , II _F , II _G	Pristinamycin I _A , I _B , I _C , I _D , I _E , I _F , I _G , I _H , I _I	<i>Streptomyces pristinaespiralis</i>
Synergistin	Synergistin A1, A2	Synergistin B1, B2, B3	
Vernamycin	Vernamycin A	Vernamycin B (α , β , γ , δ)	<i>Streptomyces olivaceus</i>
Virginiamycin	Virginiamycin M1, M2	Virginiamycin S1, S2, S3, S4, S5	<i>Streptomyces loidensis Streptomyces virginiae</i>
Semisynthetic derivatives			
Quinupristin-dalfopristin (RP 59500)	Dalfopristin (RP 54476)	Quinupristin (RP 57669)	-
Linopristin-flopristin (XRP 2868)	Flopristin (RPR 132552)	Linopristin (RPR 202868)	-

Table 2: Comparative in vitro activity (MIC in mg/l) of quinupristin-dalfopristin, and pristinamycin against Gram-positive bacteria [31-40].

Bacterial species (no. of tested isolates) ^a	Quinupristin-Dalfopristin			Pristinamycin		
	Range	MIC ₅₀	MIC ₉₀	Range	MIC ₅₀	MIC ₉₀
MS <i>Staphylococcus aureus</i> (30)	0.12-0.5	0.25	0.5	≤0.06-1	0.25	0.5
MR <i>Staphylococcus aureus</i> (45)	0.12-1	0.5	1	0.25-2	1	2
<i>Staphylococcus epidermidis</i> (14)	≤0.06-0.12	0.12	0.25	≤0.06-2	0.12	1
VS <i>Enterococcus faecalis</i> (24)	1-32	8	16	0.5-16	2	4
VanA <i>Enterococcus faecalis</i> (10)	4	8	8	2-4	4	4
VanB <i>Enterococcus faecalis</i> (23)	4-32	16	32	2-8	8	8
VS <i>Enterococcus faecium</i> (30)	0.5-2	0.5	1	0.12-2	0.25	0.5
VanA <i>Enterococcus faecium</i> (32)	0.5-32	0.5	8	0.25-32	0.25	4
VanB <i>Enterococcus faecium</i> (31)	0.25-16	0.5	4	0.12-4	0.25	2
PS <i>Streptococcus pneumoniae</i> (86)	≤0.06-1	0.5	0.5	0.12-0.5	0.25	0.25
PI <i>Streptococcus pneumoniae</i> (81)	0.12-1	0.5	1	0.12-1	0.25	0.5
PR <i>Streptococcus pneumoniae</i> (94)	0.12-1	0.5	1	0.12-1	0.25	0.5
ES <i>Streptococcus pneumoniae</i> (141)	≤0.06-1	0.5	0.5	0.12-0.5	0.25	0.25
ER <i>Streptococcus pneumoniae</i> (120)	0.25-1	0.5	1	0.12-1	0.25	0.5
<i>Streptococcus pyogenes</i> (27)	0.25-1	0.25	0.5	≤0.06-0.12	0.12	0.12
<i>Streptococcus agalactiae</i> (15)	0.5-2	1	2	0.12-0.25	0.25	0.25
Viridans streptococci (20)	0.12-4	1	4	0.25-1	0.5	0.5
<i>Listeria monocytogenes</i> (23)	0.5-1	1	1	0.25-0.5	0.5	0.5
<i>Corynebacterium jeikeium</i> (10)	≤0.06-1	0.25	0.5	0.12-0.5	0.12	0.5
<i>Actinomyces israelii</i> (13)	0.12-0.5	0.25	0.25	≤0.03-0.12	0.12	0.12
<i>Actinomyces odontolyticus</i> (10)	0.12-0.5	0.25	0.25	≤0.03-0.12	≤0.03	0.12
<i>Clostridium difficile</i> (14)	0.25-2	0.25	1	0.12-16	0.12	4
<i>Clostridium perfringens</i> (12)	0.12-0.5	0.25	0.25	0.12	0.12	0.12
<i>Fingoldia magna</i> (11) ^b	0.25-0.5	0.25	0.5	0.06-0.12	0.12	0.12
<i>Cutibacterium acnes</i> (10)	≤0.03-0.5	0.12	0.12	≤0.03-0.12	≤0.03	≤0.03
BLN <i>Haemophilus influenzae</i> (50)	1-8	2	4	0.5-2	1	2
BLP <i>Haemophilus influenzae</i> (79)	0.25-8	4	4	0.12-4	1	2
BLNAR <i>Haemophilus influenzae</i> (21)	1-8	2	4	0.25-4	1	1
BLN <i>Haemophilus parainfluenzae</i> (18)	1-16	8	16	0.5-8	4	4
BLP <i>Haemophilus parainfluenzae</i> (8)	2-32	8	16	1-8	4	4
<i>Moraxella catarrhalis</i> (30)	0.25-2	1	1	0.06-0.5	0.25	0.5
<i>Bordetella pertussis</i> (10)	0.12-0.25	-	-	0.06	-	-
<i>Neisseria meningitidis</i> (20)	0.06-1	0.25	0.5	0.03-0.25	0.06	0.12
<i>Neisseria gonorrhoeae</i> (30)	0.12-4	0.5	1	0.06-1	0.12	0.5
<i>Bacteroides fragilis</i> group (100)	0.25-4	2	2	0.5-8	2	4
<i>Bacteroides</i> spp. (50)	0.03-2	0.125	1	0.06-4	0.25	2
<i>Fusobacterium</i> spp. (40)	0.06-0.12	0.06	0.12	0.06-2	0.06	0.5
<i>Mycoplasma pneumoniae</i> (20)	0.03-0.5	0.12	0.25	0.12-0.5	0.25	0.5
<i>Mycoplasma hominis</i> (20)	0.25-4	1	2	0.25-2	0.5	0.5
<i>Ureaplasma urealyticum</i> (19)	0.5-2	1	2	0.25-2	0.5	2
<i>Legionella</i> spp. (20)	0.25-1	0.5	0.5	0.03-0.12	0.06	0.12
<i>Chlamydophila pneumoniae</i> (5)	2-4	-	-	0.5-1	-	-
<i>Chlamydia trachomatis</i> (10)	0.5-1	-	-	0.12-0.25	-	-

^aER: Erythromycin-resistant; ES: Erythromycin-susceptible; MR: Methicillin-resistant; MS: Methicillin-susceptible; PI: Penicillin-intermediate; PR: Penicillin-resistant; PS: Penicillin-susceptible; VS: Vancomycin-susceptible; BLN: β-lactamase-negative; BLNAR: β-lactamase-negative ampicillin-resistant; BLP: β-lactamase-positive.

^bFormerly *Peptostreptococcus magnus*.

Table 3: Mechanisms of resistance to streptogramins in Gram-positive bacteria (<http://faculty.washington.edu/marilynr/>) [20, 21, 24, 48-68].

Resistance mechanism	Gene(s)	Resistance phenotype ^a	Main bacterial species
Streptogramins A			
Ribosomal methylation	<i>cfr</i> , <i>cfr</i> (B), <i>cfr</i> (D)	PhLOPS _A	<i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., <i>Enterococcus</i> spp.
Acetylation	<i>vat</i> (A)-(E), <i>vat</i> (G),	S _A	<i>Staphylococcus</i> spp., <i>Enterococcus</i> spp.
Ribosomal protection	<i>vga</i> (A)-(E), <i>vga</i> (A) _v , <i>vga</i> (A) _{LC} <i>lsa</i> (A)-(C) ^c , <i>lsa</i> (E)	S _A LS _A LS _A	<i>Staphylococcus</i> spp., <i>Enterococcus</i> spp. <i>Staphylococcus</i> spp. <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., <i>Enterococcus</i> spp.
	<i>sal</i> (A) <i>eat</i> (A) _v	LS _A LS _A	<i>Staphylococcus sciuri</i> <i>Enterococcus faecium</i>
Streptogramins B			
Ribosomal methylation	<i>erm</i> genes ^b	MLS _B	<i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., <i>Enterococcus</i> spp., <i>Cutibacterium acnes</i>
Ribosomal mutation	<i>rrn</i> (23S rRNA) <i>rplD</i> (L4 protein) <i>rplV</i> (L22 protein)	MLS _B M MS _B	<i>Streptococcus pneumoniae</i> <i>Streptococcus pneumoniae</i> <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i>
Hydrolysis	<i>vgb</i> (A), <i>vgb</i> (B)	S _B	<i>Staphylococcus</i> spp., <i>Enterococcus faecium</i>
Ribosomal protection	<i>msr</i> (A)-(D), <i>msr</i> (F)-(H)	MS _B	<i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., <i>Enterococcus</i> spp., <i>Micrococcus</i> spp.

^a L: Lincosamides; M: Macrolides; O: Oxazolidinones; P: Pleuromutilins; Ph: Phenicol; S_A: Streptogramins A; S_B: Streptogramins B.

^b *erm*(A)-(C), *erm*(F), *erm*(Q), *erm*(T), *erm*(X), *erm*(Y), *erm*(34), *erm*(43)-(45), *erm*(48), *erm*(50)

^c *lsa*(C) is associated with a "LS_AP" resistance phenotype

Table 4: Main pharmacokinetic parameters of streptogramins after a single dose [29, 90-92].

Parameter ^a	Pristinamycin (2 g, PO)		Quinupristin-Dalfopristin (30:70) (7.5 mg/kg, IV)	
	PI _A	PII _A	Quinupristin	Dalfopristin
C _{max} (mg/L)	0.8	0.6	2.3-2.7	6.1-8.2
t _{max} (h)	3.2	3.1	0.9	1.1
AUC (mg•h/L)	2.2	1.2	2.7-3.3	6.5-7.7
t _{1/2} (h)	4	2.8	0.9-1.3	0.7-1.1
CL (L/h/kg)	-	-	0.7-0.9	0.7-0.8
V _d (L/kg)	-	-	0.45	0.24
PB (%)	40-45	70-80	55-78	11-26
FE (%)	-	-	75	77
UE (%)	-	-	15	19

^aAUC: area under the concentration-time curve; CL: Systemic clearance; C_{max}: Maximal plasma concentration; FE: Excretion in the faeces; IV: Intravenous; PB: Protein binding; PO: per os; t_{1/2}: Plasmatic half-life; UE: Excretion in the urine; V_d: Volume of distribution.

Table 5: Main clinical trials assessing the efficacy of pristinamycin [93-101] and quinupristin-dalfopristin [109-115].

Reference	No. of patients	Drug and dosage ^b	Duration (days)	Results (%) ^c	
				Clinical success	Bacteriological success
Acute sinusitis					
Pessey et al. [93]	160	PRI 2g/d	7-9	73-84	-
	148	CXM 500 mg/d	8-10	75-87	-
Gehanno et al. [94]	250	PRI 2 g/d	4	87-91	87
	235	CXM 500 mg/d	5	86-91	88
Community-acquired pneumonia					
Poirier et al. [96]	92	PRI 2 g/d	10-14	84-85	-
	88	AMC 2 g/d	10-14	84	-
Trémolières et al. [95]	170	PRI 3 g/d	7-10	80-88	82
	169	AMX 3 g/d	7-10	83-88	88
Acute exacerbations of COPD^a					
Léophonte et al. [97]	239	PRI 3 g/d	4	87	85
	236	AMC 2 g/d	8	88	78
Skin and soft-tissue infections					
Bernard et al. [98]	42	PRI 3 g/d	up to 10	86	-
Bernard et al. [99]	151	PRI 2 g/d	10	87	-
	142	OXA 2 g/d	10	90	-
Bernard et al. [100]	138	PRI 2-3 g/d	14	65-81	-
	150	PG 10-20 MIU/d - PV 3-6 MIU/d	14	53-67	-
Chosidow et al. [101]	163		14	81	-
	171	PRI 2 g/d CLO 2 g/d	14	83	-
MRSA infections					
Drew et al. [109]	90	QD 7.5 mg/kg q8h	28	74-76	67-71
Catheter-related staphylococcal bacteremia					
Raad et al. [110]	11	QD 5 mg/kg q8h	7	27-50	-
	15	QD 7.5 mg/kg q8h	7	27-57	-
	13	VA 1 g q12h	1	15-50	-
VRE infections					
Linden et al. [111]	396	QD 7.5 mg/kg q8h	20	51-69	60-68
Moellering et al. [113]	396	QD 7.5 mg/kg q8h or q12h	14	55-74	61
Raad et al. [112]	21	QD 7.5 mg/kg q8h	11	43	71
	19	LIN 600 mg q12h	15	58	89
Complicated SSSTIs					
Nichols et al. [114]	450	QD 7.5 mg/kg q12h	7	68	46-66
	443	OXA 2 g q6h, VAN 1 g q12h, or CFZ 1 g q8h	8	71	48-73
Nosocomial pneumonia					
Fagon et al. [115]	150	QD 7.5 mg/kg q8h + ATM 2 g	10	43-56	53-59
	148	q8h	9	45-58	55-64
		VAN 1 g q12h + ATM 2 g q8h			
Community acquired pneumonia					
Not published (NCT00653172)	302	NXL103 500 mg q12h NXL103 600 mg q12h Comparator q12h	NA	NA	NA
Acute bacterial skin infections					

Not published (NCT00949130)	180	NXL103 q12h LIN q12h	7-14 7-14	NA	NA
--------------------------------	-----	-------------------------	--------------	----	----

^aCOPD: Chronic obstructive pulmonary disease.

^bAMC: Amoxicillin-clavulanate; AMX: Amoxicillin; ATM: Aztreonam; CFZ: cefazolin; CLO: Cloxacillin; CXM: Cefuroxime axetil; LIN: Linezolid; OXA: Oxacillin; PG: Penicillin G; PV: Penicillin V; PRI: Pristinamycin; QD: Quinupristin-dalfopristin; VAN: Vancomycin

^cSuccess rates observed in per-protocol and/or intention-to-treat populations (end of treatment and/or follow-up).

NA: not available.